{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:25:05Z","timestamp":1715646305776},"reference-count":67,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Laboratory Medicine"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.cll.2023.05.003","type":"journal-article","created":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T11:23:57Z","timestamp":1687001037000},"page":"363-375","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Flow Cytometry in Diagnosis, Prognostication, and Monitoring of Multiple Myeloma and Related Disorders"],"prefix":"10.1016","volume":"43","author":[{"given":"Mikhail","family":"Roshal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.cll.2023.05.003_bib1","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world Health Organization classification of Haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.cll.2023.05.003_bib2","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.cll.2023.05.003_bib3","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multi myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.cll.2023.05.003_bib4","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A\u00a0monoclonal gammopathy precedes multi myeloma in most patients","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.cll.2023.05.003_bib5","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multi myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.cll.2023.05.003_bib6","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multi myeloma epidemiology and survival: a unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"issue":"7","key":"10.1016\/j.cll.2023.05.003_bib7","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1097\/PAS.0b013e31802d68e9","article-title":"Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: clinical correlation and insights into natural history and disease progression","volume":"31","author":"Attygalle","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"10.1016\/j.cll.2023.05.003_bib8","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1097\/PAS.0b013e3180339f18","article-title":"Epstein-Barr virus negative clonal plasma cell proliferations and lymphomas in peripheral T-cell lymphomas: a phenomenon with distinctive clinicopathologic features","volume":"31","author":"Balague","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.cll.2023.05.003_bib9","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1200\/JCO.2012.43.3797","article-title":"Angioimmunoblastic T-cell lymphoma partially obscured by an Epstein-Barr virus-negative clonal plasma cell proliferation","volume":"31","author":"Huppmann","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.cll.2023.05.003_bib10","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1053\/j.semdp.2016.05.006","article-title":"Multicentric Castleman disease: where are we now?","volume":"33","author":"Wang","year":"2016","journal-title":"Semin Diagn Pathol"},{"issue":"7","key":"10.1016\/j.cll.2023.05.003_bib11","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multi myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"Perez-Persona","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.cll.2023.05.003_bib12","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.3324\/haematol.2016.158303","article-title":"Prognostic impact of circulating plasma cells in patients with multi myeloma: implications for plasma cell leukemia definition","volume":"102","author":"Granell","year":"2017","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.cll.2023.05.003_bib13","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-018-0140-1","article-title":"Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multi myeloma","volume":"8","author":"Ravi","year":"2018","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.cll.2023.05.003_bib14","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41408-021-00587-0","article-title":"Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage","volume":"11","author":"Fernandez de Larrea","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.cll.2023.05.003_bib15","first-page":"JCO2201226","article-title":"More than 2% of circulating tumor plasma cells Defines plasma cell leukemia-like multi myeloma","author":"Jelinek","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.cll.2023.05.003_bib16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/bjh.17713","article-title":"Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia","volume":"195","author":"Bezdekova","year":"2021","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.cll.2023.05.003_bib17","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1182\/blood-2014-04-567909","article-title":"Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma","volume":"124","author":"Paiva","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cll.2023.05.003_bib18","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/bjh.13870","article-title":"Clinical features and prognostic factors in solitary plasmacytoma","volume":"172","author":"Finsinger","year":"2016","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.cll.2023.05.003_bib19","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/s12185-020-02961-3","article-title":"Retrospective analysis of plasmacytoma in Kansai myeloma Forum Registry","volume":"112","author":"Nakaya","year":"2020","journal-title":"Int J Hematol"},{"issue":"6","key":"10.1016\/j.cll.2023.05.003_bib20","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multi myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.cll.2023.05.003_bib21","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multi myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"21","key":"10.1016\/j.cll.2023.05.003_bib22","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1158\/1078-0432.CCR-22-1594","article-title":"Circulating tumor and immune cells for minimally Invasive risk stratification of smoldering multi myeloma","volume":"28","author":"Termini","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.cll.2023.05.003_bib23","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1038\/leu.2013.126","article-title":"Polyclonal immune activation and marrow plasmacytosis in multi myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance","volume":"27","author":"Zamarin","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.cll.2023.05.003_bib24","doi-asserted-by":"crossref","first-page":"100732","DOI":"10.1016\/j.blre.2020.100732","article-title":"Defining the undetectable: the current landscape of minimal residual disease assessment in multi myeloma and goals for future clarity","volume":"46","author":"Diamond","year":"2021","journal-title":"Blood Rev"},{"issue":"4","key":"10.1016\/j.cll.2023.05.003_bib25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/joim.12590","article-title":"Modern multi myeloma therapy: deep, sustained treatment response and good clinical outcomes","volume":"281","author":"Landgren","year":"2017","journal-title":"J\u00a0Intern Med"},{"issue":"1","key":"10.1016\/j.cll.2023.05.003_bib26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/cyto.b.21273","article-title":"Better therapy requires better response evaluation: paving the way for minimal residual disease testing for every myeloma patient","volume":"90","author":"Landgren","year":"2016","journal-title":"Cytometry B Clin Cytometry"},{"issue":"3","key":"10.1016\/j.cll.2023.05.003_bib27","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41375-021-01453-5","article-title":"Mortality trends in multi myeloma after the introduction of novel therapies in the United States","volume":"36","author":"Binder","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.cll.2023.05.003_bib28","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1182\/hematology.2022000404","article-title":"Newly diagnosed multi myeloma: making sense of the menu","volume":"2022","author":"Costello","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"8","key":"10.1016\/j.cll.2023.05.003_bib29","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multi myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.cll.2023.05.003_bib30","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.2021011101","article-title":"Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA","volume":"139","author":"Cavo","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cll.2023.05.003_bib31","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multi myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.cll.2023.05.003_bib32","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.2020010439","article-title":"Sustained minimal residual disease negativity in newly diagnosed multi myeloma and the impact of daratumumab in MAIA and ALCYONE","volume":"139","author":"San-Miguel","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.cll.2023.05.003_bib33","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/bmt.2016.222","article-title":"Role of MRD status in relation to clinical outcomes in newly diagnosed multi myeloma patients: a meta-analysis","volume":"51","author":"Landgren","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"25","key":"10.1016\/j.cll.2023.05.003_bib34","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of response in multi myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials","volume":"35","author":"Lahuerta","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.cll.2023.05.003_bib35","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.3324\/haematol.2015.128215","article-title":"Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen","volume":"101","author":"de Tute","year":"2016","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.cll.2023.05.003_bib36","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1182\/blood-2014-07-590166","article-title":"Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction","volume":"125","author":"Rawstron","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.cll.2023.05.003_bib37","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood.2022016782","article-title":"MRD dynamics during maintenance for improved prognostication of 1280 myeloma patients in TOURMALINE-MM3 and -MM4 trials","volume":"141","author":"Paiva","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.cll.2023.05.003_bib38","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1200\/JCO.20.01814","article-title":"Evaluation of sustained minimal residual disease negativity with daratumumab-combination Regimens in relapsed and\/or Refractory multi myeloma: analysis of POLLUX and CASTOR","volume":"39","author":"Avet-Loiseau","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"10.1016\/j.cll.2023.05.003_bib39","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1200\/JCO.21.02228","article-title":"Minimal residual disease after autologous stem-cell transplant for patients with myeloma: prognostic significance and the impact of lenalidomide maintenance and molecular risk","volume":"40","author":"de Tute","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.cll.2023.05.003_bib40","doi-asserted-by":"crossref","first-page":"e422","DOI":"10.1016\/S2352-3026(21)00130-7","article-title":"Dynamics of minimal residual disease in patients with multi myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial","volume":"8","author":"Diamond","year":"2021","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.cll.2023.05.003_bib41","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1182\/bloodadvances.2021005822","article-title":"Clinical implications of loss of bone marrow minimal residual disease negativity in multi myeloma","volume":"6","author":"Mohan","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.cll.2023.05.003_bib42","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13045-021-01135-w","article-title":"Making clinical decisions based on measurable residual disease improves the outcome in multi myeloma","volume":"14","author":"Martinez-Lopez","year":"2021","journal-title":"J\u00a0Hematol Oncol"},{"issue":"6","key":"10.1016\/j.cll.2023.05.003_bib43","doi-asserted-by":"crossref","first-page":"E193","DOI":"10.1002\/ajh.26150","article-title":"Tailored treatment to MRD response: a phase I\/II study for newly diagnosed multi myeloma patients using high dose twice-weekly carfilzomib (45 and 56\u00a0mg\/m(2)) in combination with lenalidomide and dexamethasone","volume":"96","author":"Korde","year":"2021","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.cll.2023.05.003_bib44","doi-asserted-by":"crossref","first-page":"e063037","DOI":"10.1136\/bmjopen-2022-063037","article-title":"Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multi myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II\/III randomised controlled trial","volume":"12","author":"Royle","year":"2022","journal-title":"BMJ Open"},{"issue":"19","key":"10.1016\/j.cll.2023.05.003_bib45","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1158\/1078-0432.CCR-21-1059","article-title":"Minimal residual disease in myeloma: application for clinical Care and new drug registration","volume":"27","author":"Anderson","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cll.2023.05.003_bib46","doi-asserted-by":"crossref","first-page":"800711","DOI":"10.3389\/fonc.2022.800711","article-title":"Is quantification of measurable clonal plasma cells in stem cell grafts (gMRD) clinically meaningful?","volume":"12","author":"Cengiz Seval","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.cll.2023.05.003_bib47","series-title":"CLSI","year":"2021"},{"issue":"1","key":"10.1016\/j.cll.2023.05.003_bib48","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/cyto.b.21949","article-title":"High-sensitivity flow cytometric assays: considerations for design control and analytical validation for identification of Rare events","volume":"100","author":"Sommer","year":"2021","journal-title":"Cytometry B Clin Cytom"},{"issue":"Suppl 1","key":"10.1016\/j.cll.2023.05.003_bib49","first-page":"S49","article-title":"Limit of blank, limit of detection and limit of quantitation","volume":"29","author":"Armbruster","year":"2008","journal-title":"Clin Biochem Rev"},{"issue":"10","key":"10.1016\/j.cll.2023.05.003_bib50","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multi myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.cll.2023.05.003_bib51","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1182\/bloodadvances.2016003715","article-title":"MRD detection in multi myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods","volume":"1","author":"Roshal","year":"2017","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.cll.2023.05.003_bib52","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/ajcp\/aqw052","article-title":"Single-tube 10-Fluorochrome analysis for efficient flow cytometric evaluation of minimal residual disease in plasma cell myeloma","volume":"146","author":"Royston","year":"2016","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"10.1016\/j.cll.2023.05.003_bib53","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/cyto.b.21862","article-title":"Methodological considerations for the high sensitivity detection of multi myeloma measurable residual disease","volume":"98","author":"Soh","year":"2020","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"10.1016\/j.cll.2023.05.003_bib54","article-title":"Monitoring of measurable residual disease in multi myeloma by multiparametric flow cytometry","volume":"90","author":"Soh","year":"2019","journal-title":"Curr Protoc Cytom"},{"issue":"27","key":"10.1016\/j.cll.2023.05.003_bib55","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1200\/JCO.21.01365","article-title":"Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multi myeloma","volume":"40","author":"Garces","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.cll.2023.05.003_bib56","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1182\/blood.2019002610","article-title":"Blood monitoring of circulating tumor plasma cells by next generation flow in multi myeloma after therapy","volume":"134","author":"Sanoja-Flores","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cll.2023.05.003_bib57","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.3109\/10428194.2014.955020","article-title":"Flow cytometric sensitivity and characteristics of plasma cells in patients with multi myeloma or its precursor disease: influence of biopsy site and anticoagulation method","volume":"56","author":"Manasanch","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.cll.2023.05.003_bib58","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.clml.2022.10.008","article-title":"Standardizing clinical workflow for assessing minimal residual disease by flow cytometry in multi myeloma","volume":"23","author":"Foureau","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.cll.2023.05.003_bib59","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/cyto.b.21249","article-title":"Consensus guidelines for myeloma minimal residual disease sam staining and data acquisition","volume":"90","author":"Stetler-Stevenson","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"issue":"3","key":"10.1016\/j.cll.2023.05.003_bib60","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.leukres.2013.12.007","article-title":"Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multi myeloma and its precursor diseases","volume":"38","author":"Tembhare","year":"2014","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.cll.2023.05.003_bib61","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cyto.b.21265","article-title":"Immunophenotype of normal vs. myeloma plasma cells: toward antibody panel specifications for MRD detection in multi myeloma","volume":"90","author":"Flores-Montero","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"issue":"3","key":"10.1016\/j.cll.2023.05.003_bib62","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/cyto.b.22097","article-title":"Mature B- and plasma-cell flow cytometric analysis: a review of the impact of targeted therapy","volume":"104","author":"Gao","year":"2023","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"10.1016\/j.cll.2023.05.003_bib63","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/cyto.b.21269","article-title":"Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases","volume":"90","author":"Pojero","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"issue":"4","key":"10.1016\/j.cll.2023.05.003_bib64","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/cyto.b.21961","article-title":"CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab","volume":"100","author":"Soh","year":"2021","journal-title":"Cytometry B Clin Cytom"},{"issue":"13","key":"10.1016\/j.cll.2023.05.003_bib65","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-Targeted CAR T\u00a0cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.cll.2023.05.003_bib66","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/s41467-020-14619-z","article-title":"CD229 CAR T\u00a0cells eliminate multi myeloma and tumor propagating cells without fratricide","volume":"11","author":"Radhakrishnan","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.cll.2023.05.003_bib67","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.leukres.2018.07.015","article-title":"Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma","volume":"71","author":"Salem","year":"2018","journal-title":"Leuk Res"}],"container-title":["Clinics in Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271223000537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271223000537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T10:09:34Z","timestamp":1715594974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272271223000537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0272271223000537"],"URL":"https:\/\/doi.org\/10.1016\/j.cll.2023.05.003","relation":{},"ISSN":["0272-2712"],"issn-type":[{"value":"0272-2712","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Flow Cytometry in Diagnosis, Prognostication, and Monitoring of Multiple Myeloma and Related Disorders","name":"articletitle","label":"Article Title"},{"value":"Clinics in Laboratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cll.2023.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}